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Introduction
The most common form of 
lymphoma, diffuse large B-cell 
lymphoma (DLBCL), is often 
characterized by gene duplication of 
TCF4, an E2 basic helix-loop-helix 
transcription factor. The TCF4 gene 
is closely related to TCF3, which is 
negatively regulated by ID2 and ID3. 
The ID proteins negatively regulate 
cellular differentiation and induce 
proliferation by inhibiting the activity 
of TCF3 and TCF4 through 
heterodimer formation. Due to their 
implication in tumorigenesis, these 
genes may be potential therapeutic 
targets for DLBCL tumors resistant 
to current immuno-chemotherapies. 
The CRISPR-Cas9 system is an 
effective tool for editing the genome 
of human cancer cell lines. For cell 
lines that are difficult to transfect, 
electroporation facilitates the entry 
of a designed guide RNA and Cas9 
nuclease. DNA repair can then 
occur by one of two pathways: non-
homologous end joining or 
homology-directed repair. The 
resulting knockout of a gene or 
introduction of a specific mutation 
allows for study of cancer prognosis 
and treatments.
Conclusions
CRISPR-Cas9 editing of the ID3 
gene resulted in indel mutations in 
two clones, A4 and B12. These 
mutations alter the reading frame,
causing a frame shift.
To test whether this effectively 
knocked out the gene, a western 
blot was performed. The A4 and 
B12 lines produced no ID3 protein 
band, meaning little to no 
expression occurred. Thus, these 
edited lines may be effective tools
for studying tumorigenesis and the 
interaction between ID3 and TCF3. 
In addition, future studies could be 
done using the cancer drugs 
OTX015 and Venetoclax.
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Fig. 2 The CRISPR-Cas9 system successfully edited the ID3 gene. The DG-75 clone B15 
was transfected with PX458-ID3-g1 using an electroporation protocol. Sequencing of cell 
clones identified whether indel mutations occurred in the ID3 gene. Clone A4 had one guanine  
inserted, clones A20 and B3 were not edited, and clone B12 had one guanine deleted.
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Methodology
Electroporation and the CRISPR-
Cas9 system were used to introduce
insertion-deletion (indel) mutations in
the ID3 gene. Sequencing was 
performed to characterize any 
resulting mutations.
Western blotting determined whether 
mutations affected the expression of 
the ID3 protein in each respective
clone compared to wild type.
Fig. 3 Indel mutations in the ID3 
gene resulted in an absence of 
protein expression. A western blot 
was performed to determine the 
presence of the ID3 protein. Clones
A20 and B3 were unedited and 
expressed ID3, as indicated by the 
presence of a band. The edited
clones, A4 and B12, do not show
expression, similar to the negative
control HBL-1, an established 
DLBCL cell line.
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Fig. 1a Cas9 nuclease and 
guide RNA form a complex 
capable of creating a double 
stranded break in DNA.
Fig. 1b Repair of the cleaved 
DNA leads to the insertion or 
deletion of base pairs. Indel 
mutations may lead to a 
truncated or non-functional 
protein.
